Synaptogenix (NASDAQ:TAOX) Trading Down 10.4% – What’s Next?

Shares of Synaptogenix, Inc. (NASDAQ:TAOX – Get Free Report) traded down 10.4% during mid-day trading on Friday . The stock traded as low as $3.29 and last traded at $3.29. Approximately 130,224 shares were traded during trading, an increase of 51% from the average session volume of 86,513 shares. The stock had previously closed at $3.67.

Wall Street Analyst Weigh In

Several research firms have recently commented on TAOX. Wall Street Zen raised Synaptogenix from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Synaptogenix in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Synaptogenix currently has a consensus rating of “Sell”.

Get Synaptogenix alerts:

Check Out Our Latest Report on TAOX

Synaptogenix Stock Down 10.4%

The company’s 50 day moving average is $3.88 and its 200 day moving average is $4.58. The firm has a market capitalization of $24.58 million, a price-to-earnings ratio of -0.25 and a beta of 1.42.

Synaptogenix (NASDAQ:TAOX – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.43 EPS for the quarter. The business had revenue of $5.96 million for the quarter.

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.

Further Reading

• Five stocks we like better than Synaptogenix
• Telecom Earnings Reveal a Sector That Finally Looks Healthier
• Defense Earnings Show Readiness Now and Modernization Ahead
• Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
• MarketBeat Week in Review – 07/20- 07/24

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.